Skip to main content
Enter your keywords
User account menu
Log in
Main navigation
About
History & Impact
Mission & Values
Leadership
Support SWOG
Join SWOG
Policies & Procedures
Careers
Contact Us
The SWOG Network
How We Work
Our Staff
Our Advocates
Our Partners
News & Events
News
SWOG Stories
SWOG Meetings
For Press
Clinical Trials
Biospecimen Submission
Biospecimen Access
Clinical Trials Search
Clinical Research Resources
Frequently Asked Questions
Publications
Institutions
Quality Assurance & Audits
Serious Adverse Events
Training Resources
CRA Workbench
Protocol Workbench
For Patients
Patient & Advocate Voices
Trials Open to Patients
About SWOG Cancer Trials
Joining a Trial
Glossary
Section navigation
Recent Updates
5/15/2024
5/1/2024
4/15/2024
4/1/2024
3/15/2024
3/1/2024
2/15/2024
2/1/2024
1/15/2024
1/1/2024
12/15/2023
12/1/2023
All Updates
Breadcrumb
SWOG
Member Resources
Trial & Business Updates
Immunomolecular Therapeutics
Priority List Immunomolecular Therapeutics
S2101
II
Biomarker Stratified CaboZantinib and NivOlumab (BiCaZO) - A phase II study of combining cabozantinib and nivolumab in patients with advanced solid tumors stratified by tumor biomarkers
EAY191-S3
II
Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Patients with AKT-Altered Advanced Non-Breast Solid Tumors
CTSU/AHOD2131
III
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
CTSU/A151804
Other
ESTABLISHMENT OF A NATIONAL BIOREPOSITORY TO ADVANCE STUDIES OF IMMUNE-RELATED ADVERSE EVENTS